AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Proprotein convertase subtilisin/kexin type 9 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Proprotein convertase subtilisin/kexin type 9 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Proprotein convertase subtilisin/kexin type 9, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Proprotein convertase subtilisin/kexin type 9. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Proprotein convertase subtilisin/kexin type 9. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Proprotein convertase subtilisin/kexin type 9 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Proprotein convertase subtilisin/kexin type 9
partner:
Reaxense
upacc:
Q8NBP7
UPID:
PCSK9_HUMAN
Alternative names:
Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9
Alternative UPACC:
Q8NBP7; A8T640; C0JYY9; Q5PSM5; Q5SZQ2
Background:
Proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as Neural apoptosis-regulated convertase 1, plays a pivotal role in cholesterol homeostasis. It binds to and promotes the degradation of receptors crucial for low-density lipoprotein (LDL) clearance, such as LDLR and VLDLR. PCSK9's influence extends to modulating epithelial sodium channels, impacting sodium absorption.
Therapeutic significance:
Given its central role in regulating LDL cholesterol levels, PCSK9 is directly implicated in familial hypercholesterolemia, a condition leading to premature coronary heart disease. Targeting PCSK9 offers a promising avenue for therapeutic intervention in managing elevated cholesterol levels and associated cardiovascular risks.
